Treatment of severe psoriasis with infliximab: Report of two cases

Acta Dermatovenerologica Croatica

Volumn 17, Issue 3, 2009, Pages 204-208

  Peternel, Sandra ^a,b   Prpić Massari, Larisa ^a   Guina, Tina ^a   Novak, Srdan ^b   Brajac, Ines ^a   Kaštelan, Marija ^a  

^a Referral Ctr for Psoriasis of the Ministry of Health and Social Welfare of the Republic of Croatia   (Croatia)

^b KBC RIJEKA   (Croatia)

Author keywords

Infliximab; Psoriasis; Psoriatic arthritis

Indexed keywords

C REACTIVE PROTEIN; DICLOFENAC; ETRETIN; FOLIC ACID; IBUPROFEN; INFLIXIMAB; METHOTREXATE; STEROID;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; REMISSION; SCORING SYSTEM; SKIN MANIFESTATION; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PSORIASIS;

EID: 70349653687     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-850
2. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-873
3. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003;49:S57-61.
4. Remicade [Full U.S. prescribing information]. Available from: URL:http://www.centocor.com/centocor/assets/remicade.pdf.
5. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-1236 (Pubitemid 40530131)
6. Reich K, Nestle FO, Papp K, Ortonne J, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet 2005;366:1367-1374 (Pubitemid 41443403)
7. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-151 (Pubitemid 24213812)
8. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaquetype psoriasis. J Biol Regul Homeost Agents 1997;11:115-118 (Pubitemid 28045966)
9. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003;48:829-835 (Pubitemid 36706213)
10. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006;154:1161-1168 (Pubitemid 43727400)
11. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-542 (Pubitemid 39278071)
12. Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 2006;155:160-169 (Pubitemid 43876410)
13. Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007;156:329-336 (Pubitemid 46095962)
14. Ogilvie ALJ, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, et al. Treatment of psoriatic arthritis with antitumor necrosis-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587-589 (Pubitemid 32232017)
15. Baert F, De Vos M, Louis E, Vermeire S; Belgian IBD Research Group. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol Belg 2007;70(2):163-170
16. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-924 (Pubitemid 36389794)
17. Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, et al. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008;58:94-105. (Pubitemid 350302037)
18. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factoralpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008;9:1-14.
19. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.